The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection.
New research supports the theory that HIV latency occurs when HIV infects a CD4 T cell that is in the process of transitioning from an activated state to a resting state.
Although the goals of an HIV vaccine or cure remain elusive, the research being done makes these goals appear increasingly likely.
The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.
Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...
It has been fascinating to observe the evolution in HIV clinicians' thinking on long-acting injectable antiretrovirals (LA-ART). It was not that long ago that LA-ART was largely dismissed as suiting only a small niche of patients while most were assu...
Researchers are flipping the idea of latency reversal on its head. Their approach -- which they have dubbed block and lock -- involves trying to imprison latent HIV in a way that prevents it from ever reactivating.
A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.
Researchers are attempting to establish how to make long-term HIV remission possible after finding that HIV can be suppressed naturally in some people for a long time after they have been on a short spell of treatment.
An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.